LTRN
Lantern Pharma Inc
NASDAQ: LTRN · HEALTHCARE · BIOTECHNOLOGY
$0.77
+20.89% today
Updated 2026-10-28
Market cap
$9.49M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-1.63
Dividend yield
—
52W range
$1 – $4
Volume
0.3M
WallStSmart proprietary scores
17
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C5.0
Quality
C+3.0
Profitability
D5.0
Valuation
C+1/9
Piotroski F-Score
Weak
-15.4
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →271 stocks currently score above 75
Price targets
Analyst target
$17.50
+2161.86%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
Price chart
Stock snapshot
Strengths
+ Debt/equity -0.01x — low leverage
Risks
- Piotroski 1/9 — weak financial health
- Altman Z -15.38 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-2.94M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-14.26B | $-15.96M | $-20.78M | $-17.12M | $-7.07M |
| EPS | — | — | — | — | $-1.63 |
| Free cash flow | $-12.80M | $-14.37M | $-17.83M | $-15.68M | $-2.94M |
| Profit margin | — | — | — | — | — |
Peer comparison
Smart narrative
Lantern Pharma Inc trades at $0.77. Our Smart Value Score of 17/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of -15.38, it sits in the distress.
Frequently asked questions
What is Lantern Pharma Inc's stock price?
Lantern Pharma Inc (LTRN) trades at $0.77.
Is Lantern Pharma Inc overvalued?
Lantern Pharma Inc carries a Smart Value Score of 17/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Lantern Pharma Inc (LTRN)?
The 12-month analyst consensus target is $17.50, about 2161.9% above the current $0.77. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
Lantern Pharma Inc's Altman Z-Score is -15.38, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-157.40%
Beta2.32
50D MA$1.48
200D MA$2.53
Shares out0.01B
Float0.01B
Short ratio—
Avg volume0.3M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—